A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to determine the recommended phase II dose of weekly intravenous
topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous
temsirolimus in patients with and without prior pelvic radiation.